Home › Free Stock Grades › DNTH
Dianthus Therapeutics, Inc. (DNTH) Stock Grade
DNTH · Healthcare
C-
Market Cap
$1.6B
P/E Ratio
—
Revenue Growth (YoY)
-67.4%
Net Margin
-7973.3%
Return on Equity
—
Dividend Yield
None
About Dianthus Therapeutics, Inc.'s fundamentals
Dianthus Therapeutics is a biotechnology company with a market capitalization of $1.6 billion that is currently unprofitable, reporting a significant net loss in its latest annual statement with a net margin of -7973.3%. The company experienced a substantial decline in revenue, contracting 67.4% year-over-year, indicating a sharp drop in sales performance. With no dividend payments and negative profitability metrics, the company is in a development or recovery phase typical of early-stage biotech firms that prioritize research and development spending over current earnings.